Holen Sie sich die Stockscreener-App
1.50
1.96%
-0.03
Vorhandelsmarkt:
1.44
-0.06
-4.00%
Cocrystal Pharma Inc Aktie (COCP) Neueste Nachrichten
Smart Money: Can Cocrystal Pharma Inc deliver consistent EPS growth2026 Technical Patterns & Daily Growth Stock Tips - baoquankhu1.vn
Why Cocrystal Pharma Shares Are Cooling Off Monday? - MSN
COCP stock soars 75% — what is the link to Cocrystal’s norovirus treatment? - MSN
Investor Mood: Is Cocrystal Pharma Inc benefiting from innovation trendsQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Tech Rally: Is Cocrystal Pharma Inc stock risky to hold nowMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention - Zacks Small Cap Research
Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance UK
COCP PE Ratio & Valuation, Is COCP Overvalued - Intellectia AI
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - Yahoo Finance
Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight - meyka.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988 - Sahm
FDA grants fast track status to Cocrystal’s norovirus drug By Investing.com - Investing.com Australia
Cocrystal Pharma stock surges on FDA Fast Track designation By Investing.com - Investing.com South Africa
Cocrystal Pharma (COCP) Receives FDA Fast Track Status for Norov - GuruFocus
Cocrystal Pharma stock surges on FDA Fast Track designation - Investing.com
Cocrystal Pharma, Inc. (8CC.F) stock price, news, quote and history - Yahoo Finance UK
Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom - StocksToTrade
Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug - TipRanks
COCP Stock Soars 75% — What Is The Link To Cocrystal’s Norovirus Treatment? - Stocktwits
Cocrystal Pharma Advances Antiviral Trials Amid Financial Strategy Shift - timothysykes.com
FDA grants fast track status to Cocrystal’s norovirus drug - Investing.com
FDA Fast Track backs Cocrystal (Nasdaq: COCP) oral norovirus antiviral CDI-988 - Stock Titan
Cocrystal Pharma, Inc. announced that its antiviral candidate drug Cdi-988 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). - Bitget
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - GlobeNewswire
COCP gets FDA Fast Track for CDI-988 norovirus drug, stock up 75% | Tap to know more | Inshorts - Inshorts
Cocrystal begins norovirus challenge study, reports 2025 results By Investing.com - Investing.com South Africa
Cocrystal Pharma Reports 2025 Financial Results and Advances Norovirus and Influenza Antiviral Drug Pipeline - Minichart
Cocrystal Pharma 2025 Research and Development Expenses $5.1M >COCP - Moomoo
Cocrystal Pharma Reports 2025 Financial Results, Advances Antiviral Drug Programs - National Today
Cocrystal Pharma Reports 2025 Financial Results - National Today
[10-K] Cocrystal Pharma, Inc. Files Annual Report - Stock Titan
Cocrystal begins norovirus challenge study, reports 2025 results - Investing.com
Cocrystal Pharma 2025 10-K: $0 Revenue, $(0.78) EPS, $(8.83)M Net Loss - TradingView
Cocrystal Pharma reports 2025 net loss $8.8M, cash $7.7M, advances norovirus CDI-988 into Phase 1b - TradingView — Track All Markets
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cocrystal Pharma (NASDAQ: COCP) cuts 2025 loss to $8.8M and advances antivirals - Stock Titan
Cocrystal Pharma, Inc. recently released its financial report for fiscal year 2025 and provided an update on the latest progress in its antiviral drug development projects. - Bitget
Cocrystal Pharma 2025 net loss narrows as R&D expenses fall - TradingView
BRIEF-Cocrystal Pharma FY Net Income USD -8.831 Million - TradingView — Track All Markets
No approved norovirus drug exists. Cocrystal now tests one in humans - Stock Titan
Form 8-KCurrent report - ADVFN
Institution Moves: Can Cocrystal Pharma Inc ride the EV waveEarnings Recap Report & Real-Time Volume Surge Alerts - baoquankhu1.vn
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):